Evolution of Personalized Medicine:
The Role of Pharmacogenomics in Managed Care
Post Test

A score of 70% must be achieved to receive continuing education credits.
 
1. Managed care cost shifting will increasingly challenge the individual consumer’s ability to access health care in the US.
   True
   False
2. The importance of biomarkers in treatment selection and patient management is only anticipated to increase in the coming years.
 True
 False
3. The value of personalized medicine is the same for all patients.
  True
 False
4. All of the following are current examples of genomic tests used to determine treatment selection except:
 a. HER2
 b. KRAS/EGFR
 c. OncoType DX
 d. PGx Predict
 e. All of the above are current examples
5. Changes to FDA labels will accelerate the uptake and application of personalized medicine.
 True
 False
6. All of the following are examples of how diagnostics can “personalize” medicine except:
  a. Risk stratification
  b. Prognostic testing
 c. Treatment monitoring
 d. All of the above
7. OncoType DX (for breast cancer treatment) is the forerunner of complex tests to receive payer coverage by Medicare and private health plans.
  True
 False
8. Medical devices and Diagnostics are very similar to Drugs and Biologics.
  True
  False
9. More than 60% of US Medical Directors define “clinical utility” as “a change in patient management.”
   True
   False
10. Choose the correct clinical analytical framework for assessing new health technologies:
   a. Screening; predictive testing; diagnosis; treatment selection; treatment; prognosis; monitoring
   b. Predictive testing; screening; diagnosis; treatment selection; treatment; prognosis; monitoring
   c. Screening; predictive testing; diagnosis; treatment selection; treatment; monitoring; prognosis
   d. Predictive testing; screening, diagnosis, treatment selection, treatment, monitoring, prognosis
 


Evolution of Personalized Medicine:
The Role of Pharmacogenomics in Managed Care
 

Evaluation Summary
Please rate this activity on the following scale:
4 - Excellent        3 - Good        2 - Fair        1 - Poor
1. Based on the content presented I am better able to:  
  • Define personalized medicine, pharmacogenomics and pharmacogenetics
    4        3        2        1
  • Identify the value of personalized medicine in the future of healthcare
    4        3        2        1
  • Describe how personalized medicine is used in determining treatment plans
    4        3        2        1
  • Identify the role of pharmacogenetics testing
    4        3        2        1
  • Describe the impact of pharmacogenetics on patient outcomes and the practice of medicine
    4        3        2        1
2. Activity met my expectations    4        3        2        1  
3. Activity was free of bias    4        3        2        1
4. Activity content was understandable    4        3        2        1
5. Presenter was free of bias    4        3        2        1
6. Method of learning was beneficial    4        3        2        1
7. Presenter covered material to extent expected    4        3        2        1


Due to the content of this activity, I will change my practice patterns by:

Providing appropriate education to patients on personalized medicine
Work with our primary care providers to establish appropriate use of genomic testing
My practice patterns will not change
Other    Specify:

Continuing education implies quality improvement in behavior. As part of our quality improvement process, NAMCP/AAMCN will contact you six months from your post test submission to monitor change.
Name:  
Profession: MD  DO  RN  LPN  Other
Company:  
Mailing Address:  
City, State, Zip:  
Phone:  
Fax:  
Email:  
Heard About Activity By: eNews  Colleague  Internet    JMCM Article
 Email   Phone
 
Send my certificate by: U.S. Mail             Email
 

Help us cut down spam.

Type the number 411 into
the following box (Required)